ReviewInternational journal of nanomedicine2025
Nanotechnology-Enhanced Extracellular Vesicles -Based Chipsets in Early Cancer Detection and Theranostics.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Exploring the roles of fungal extracellular vesicles in fungal pathogenesis and symbiosis: Current understandings and future perspectives.World journal of microbiology & biotechnology · 2026Review
- Exosome-Based Liquid Biopsy in Biliary Tract Cancer: Nanotechnology-Enabled Strategies and Future Perspectives.International journal of nanomedicine · 2026Review
- Extracellular Vesicles in Peripheral Nerve Regeneration: From Biology to Therapeutic Engineering.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology has revolutionized cancer diagnostics, particularly through exosome-based chipsets that offer early, non-invasive, and highly sensitive detection. These nanoscale platforms isolate and analyze extracellular vesicles (exosomes) carrying molecular signatures from cancer cells. Microfluidic and material science innovations enable detection from body fluids with high specificity, surpassing conventional diagnostic tools. Engineered exosomes also offer therapeutic potential, especially in targeting metastasis. This review explores exosome formation, roles in cancer, and the latest advancements in chipset technology, emphasizing their diagnostic and therapeutic potential. Despite challenges in standardization and clinical integration, ongoing research and trials indicate a transformative shift in cancer care driven by exosome-based technologies. Special emphasis is placed on chip-integrated nanotechnologies developed for exosome isolation and analysis, detailing recent innovations, device specifications, and diagnostic potential. The review aims to bridge the gap between fundamental exosome biology and the translational relevance of chip-based platforms in clinical cancer diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.